Tuvero (fimasartan/rosuvastatin)
/ Boryung Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 12, 2023
FIMARO: Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control
(clinicaltrials.gov)
- P=N/A | N=541 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Unknown status ➔ Completed | N=1056 ➔ 541
Enrollment change • Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
1 to 1
Of
1
Go to page
1